Vertex Pharmaceuticals, Inc. (VRTX)
|Net Income (ttm)||3.19B|
|Day's Range||288.65 - 296.95|
|52-Week Range||176.36 - 296.95|
|Price Target||303.97 (+3.4%)|
|Earnings Date||Aug 4, 2022|
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical tri... [Read more...]
In 2021, VRTX's revenue was $7.57 billion, an increase of 22.06% compared to the previous year's $6.21 billion. Earnings were $2.34 billion, a decrease of -13.63%.Financial Statements
According to 35 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 303.97, which is an increase of 3.41% from the latest price.
Vertex Pharmaceuticals is showing is showing green check marks across the board, and today we will look at a bullish option strategy. The post Bull Call Spread On Vertex Pharmaceuticals Taps Into Stock'...
Vertex Pharmaceuticals made a bullish move on earnings amid a confirmed market rally, leading five stocks to watch this week. The post Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch ap...
Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals Finds Support After Earnings
The stock market fell sharply early Friday on news of strong job growth in July, but indexes pared losses by the close. The post Stock Market Takes Bullish Jobs Report In Stride; Vertex Pharmaceuticals ...
The company's popular Trikafta continues to boost the fundamentals.
Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.
Vertex (VRTX) delivered earnings and revenue surprises of 3.45% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals said its triple-regimen in cystic fibrosis is gaining new users abroad. VRTX stock jumped late Thursday.
BOSTON--(BUSINESS WIRE)--Vertex Reports Second Quarter 2022 Financial Results
With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Inv...
This stock checks off all the boxes.
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These companies have cornered the right markets and are chasing the right long-term trends.
Vertex's good news has been multiplying.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that following the positive Phase 2 results earlier this year and having reached agreement on the design of th...
These businesses are full of growth potential.
Final Trades: Foot Locker, Vertex, BlackRock & more
The "Halftime Report" traders give their top picks to watch for the second half.
When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet these ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The compa...
These drugmakers can help you get through the bear market.
Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?
Today's reaction to a high CPI print is the opposite of what we saw last month.
Vertex (VRTX) will acquire ViaCyte for $320 million in cash.